Compare ACM Research Inc (ACMR) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs Crispr Therapeutics AG — how do they compare? ACM Research Inc trades at $98 (market cap $6.54B), while Crispr Therapeutics AG trades at $59.25 (market cap $5.98B). The key difference: ACM Research Inc and Crispr Therapeutics AG are close in size by market cap, and ACM Research Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| ACMR | CRSP | |
|---|---|---|
Market Cap | $6.54B | $5.98B |
Sector | Technology | Health |
52-Week High | $126.89 | $76.78 |
52-Week Low | $23.92 | $44.34 |
Enterprise Value | $5.61B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
CRISPR Therapeutics (CRSP) trades at $60.77, up 1.15% with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company maintains strong cash reserves despite negative profitability metrics, with recent FDA approval for Casgevy pediatric use expanding its commercial potential. Technical indicators show the stock trading near pivot point resistance at $61 with RSI levels suggesting potential overbought conditions.
While CRSP shows promising growth potential with its pioneering gene-editing technology and recent regulatory wins, investors face significant risks from persistent negative margins and cash burn. The stock offers 19.6% upside to the consensus price target of $72.67, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
